EMG1: A Potential Drug Target or Biomarker for various Diseases

Target Name: EMG1

NCBI ID: G10436

EMG1

EMG1: A Potential Drug Target or Biomarker for various Diseases

EMG1 (EMG1 N1-specific pseudouridine methyltransferase, transcript variant 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and regulation have been extensively studied, and its potential as a drug target continue to attract researchers' interest.

EMG1 is a non-coding RNA molecule that is expressed in various tissues and cells in the body. It is a key regulator of pseudouridine methylation, a post-translational modification that plays a crucial role in various cellular processes, including DNA replication, gene expression, and cell signaling. Pseudouridine methylation is a highly dynamic modification that can either activate or repress gene expression. It is tightly regulated by DNA methylation complex, which consists of DNA methyltransferase (DNMTase) and DNA methyltransferase-like (DNMTase-like) proteins.

EMG1 is a key regulator of pseudouridine methylation in various tissues and cells. Its function in neural development and function, including the regulation of neuronal excitability and synaptic plasticity, makes it an attractive target for drug development. Studies have shown that EMG1 is highly expressed in neural tissues, including brain, spinal cord, and muscle, and that its levels are decreased in various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression.

In addition to its potential as a drug target, EMG1 is also a potential biomarker for various diseases. Its expression is often reduced in tissues and cells affected by cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that EMG1 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Its levels are also decreased in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

EMG1's potential as a drug target is based on its unique mechanism of action and its expressed role in various biological processes. One of the key advantages of EMG1 is its ability to modulate pseudouridine methylation in a targeted and reversible manner. This allows for the regulation of gene expression at the post-translational level, which can be difficult to achieve with some other molecules. Additionally, EMG1 is a versatile regulator, as it can be used to target both RNA and DNA-mediated modifications.

Another promising aspect of EMG1's potential as a drug target is its diverse range of effects across various tissues and cells. Its expression is often reduced in various tissues, including the brain, and its levels are associated with various neurological and psychiatric disorders. This suggests that EMG1 may have a broad range of effects across various biological processes, including neuronal function and disease.

In conclusion, EMG1 is a gene that has great potential as a drug target or biomarker for various diseases. Its unique mechanism of action and its expressed role in various biological processes make it an attractive target for drug development. Further research is needed to fully understand the functions of EMG1 and its potential as a drug or biomarker.

Protein Name: EMG1 N1-specific Pseudouridine Methyltransferase

Functions: S-adenosyl-L-methionine-dependent pseudouridine N(1)-methyltransferase that methylates pseudouridine at position 1248 (Psi1248) in 18S rRNA. Involved the biosynthesis of the hypermodified N1-methyl-N3-(3-amino-3-carboxypropyl) pseudouridine (m1acp3-Psi) conserved in eukaryotic 18S rRNA. Is not able to methylate uridine at this position (PubMed:20047967). Has also an essential role in 40S ribosomal subunit biogenesis independent on its methyltransferase activity, facilitating the incorporation of ribosomal protein S19 during the formation of pre-ribosomes (By similarity). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797)

The "EMG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets